-
Global hot target new drug market pattern in 2020
Time of Update: 2021-03-23
Note: The data for 2020 does not include Carrelizumab (Hengrui), Tereprizumab (Junshi), Bavencio (Merck/Pfizer), Opdivo (Ono Pharmaceutical), 4 companies totaling approximately US$2 billionFrom the perspective of specific drug market realization, Keytruda continues to rise, with global sales increasing by 30%, reaching 14.
-
The National Food and Drug Administration approved the listing of Qingfei Paidu Granules, Huashibaidu Granules, and Xuanfeibaidu Granules
Time of Update: 2021-03-23
(CCTV reporter Yu Jingying) Medical Network, March 3 News On March 2, the National Medical Products Administration approved the Qingfei Paidu Granules of the Institute of Clinical Basic Medicine of Chinese Academy of Chinese Medical Sciences, the Huashibaidu Granules of Guangdong Yifang Pharmaceutical Co.
-
Fosun Pharma executives change!
Time of Update: 2021-03-23
Li Dongjiu, born in March 1965, is currently the Senior Vice President of Fosun Pharma.
(stock code: 01099), a company listed on the Hong Kong Stock Exchange Director, Vice President and General Counsel of Sinopharm Holdings Co.
-
National Food and Drug Administration: These devices are recalled at the highest level
Time of Update: 2021-03-23
Medical Network News on March 5 Sales in China First level recall On March 3, the State Food and Drug Administration announced that Poco International Medical Trading (Shanghai) Co.
-
Global pharmaceutical companies ranked TOP10! Johnson and Johnson, Roche, Novarter...
Time of Update: 2021-03-23
According to the revenue statistics of the pharmaceutical business, the top 10 global pharmaceutical companies are ranked in order: Roche, Novartis, AbbVie, Johnson & Johnson, Merck, Bristol-Myers Squibb, Pfizer, Sanofi, GlaxoSmithKline, and Takeda.
-
GlaxoSmithKline/Vir suspends monoclonal antibody VIR-7831 and enrolls in key phase 3 clinical patients
Time of Update: 2021-03-23
Vir Biotechnology and GSK provide update on NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
-
The State Drug Administration issued a document: 226 drugs written off
Time of Update: 2021-03-23
Low drug prices make pharmaceutical companies withdraw from the market The drugs with the highest number of cancellations this time are acetaminophen tablets and captopril tablets, and seven approvals have been cancelled respectively.
-
AZ new crown vaccine real world data released, one shot reduces the risk of illness and hospitalization in the elderly
Time of Update: 2021-03-23
The current accumulated data shows that the effectiveness of this vaccine in preventing symptomatic COVID-19 reaches 60-73% in elderly people over 70 years old, 4 weeks after a single vaccination.
-
Strengthen the grassroots, how to improve the path?
Time of Update: 2021-03-23
Huo Yong: To establish an effective disease and health management systemHuo Yong: To establish an effective disease and health management systemMember of the National Committee of the Chinese People's Political Consultative Conference and Director of the Heart Center of Peking University First Hospital Huo Yong"The core of building an efficient and high-quality medical service system lies in medical staff.
-
The Food and Drug Administration collectively interviewed 73 principals in charge of pharmaceutical companies
Time of Update: 2021-03-23
Relevant business offices, inspection branches, and directly affiliated units of the provincial bureau, as well as the actual controllers or legal representatives, quality leaders, and production leaders of the province’s 73 pharmaceutical manufacturing companies attended the meeting.
-
Background interpretation of the current round of revision of the Regulations on the Supervision and Administration of Medical Devices
Time of Update: 2021-03-23
34 ，。200014《》（《》），《》、、、。，，20142017、、。 20201221，《（）》（《》）。《》、、。 《》，： ：，、 20，800025000，，。 2014， 20%，。15%，。 2020，，，。，。，。。 ：， 2017“”《》，、、，。 1. 。201712，《（）》，，，。20198，《》，、、、、、、。，，，。 《》，、、、、；、、。 2
-
Puli Pharmaceuticals: Azithromycin for injection was approved by Thailand Food and Drug Administration
Time of Update: 2021-03-23
Azithromycin for injection is suitable for community-acquired pneumonia and pelvic inflammatory diseases caused by sensitive pathogens.
Community-acquired pneumoniaPatients who are caused by pathogenic bacteria such as Chlamydia pneumoniae, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae, Staphylococcus aureus, or Streptococcus pneumoniae, and the initial treatment requires intravenous administration.
-
February 2021 | TOP5 failed clinical studies
Time of Update: 2021-03-23
Phase III study of BAT8001 in the treatment of breast cancerOn the evening of February 8, Biotech issued an announcement stating that the phase III clinical efficacy index of the HER2 ADC drug BAT8001 did not reach the preset level of progression-free survival (PFS) compared with the control group (lapatinib combined with capecitabine) The goal of superiority.
-
Implementation of the new version of the medical insurance catalogue, 119 national talks officially reduced the price of drugs
Time of Update: 2021-03-23
Tilelizumab: For example, BeiGene's star product tislelizumab (BaiZian), the indication for entering the medical insurance this time is the treatment of relapsed or refractory classic Hodgkin's lymphoma after at least second-line chemotherapy; PD- The failure of platinum-containing chemotherapy with high L1 expression includes the treatment of locally advanced or metastatic urothelial carcinoma that has progressed within 12 months of neoadjuvant or adjuvant chemotherapy.
-
Rare disease day focuses on multiple sclerosis
Time of Update: 2021-03-23
Among them, multiple sclerosis (MS) is a rare disease, and many drugs have been approved in recent years.
In August 2020, ofatumumab subcutaneous injection was approved by the FDA for the treatment of adult relapsing multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
-
The new version of the medical insurance catalog is implemented today!
Time of Update: 2021-03-23
On December 28, the results of the 2020 medical insurance negotiations were announced.
A total of 162 drugs were negotiated and 119 negotiations were successful.
-
Orphan drug research and development progress 5 pictures in seconds
Time of Update: 2021-03-23
Because of the small number of patients with rare diseases, low market demand, and high research and development costs, companies are not very enthusiastic about developing orphan drugs, but because all countries have introduced them A series of encouraging policies have been adopted.
-
The local government was investigated for monopolizing the purchasing power of consumables and pharmaceutical equipment distribution!
Time of Update: 2021-03-23
Strengthen anti-monopoly law enforcement Focus on the fields of medicine, bidding and government procurement When it comes to preventing the abuse of administrative power to restrict competition, I have to talk about the recent comprehensive clean-up of regulations and practices that hinder the unified market and fair competition in the Guangdong-Hong Kong-Macao Greater Bay Area.
-
Well-known pharmaceutical companies have been exposed to withdraw insulin product-related promotion posts. Is the shock wave coming?
Time of Update: 2021-03-23
According to the agreement, 3SBio will use its national sales network and build on the existing Metabolic Products Business Unit to form a more extensive marketing and promotion team for diabetes products (including Humulin®).
-
Tianyao's Tameasone Sodium Phosphate API passed the technical review of the NMPA Drug Evaluation Center
Time of Update: 2021-03-23
announced that the company’s betamethasone sodium phosphate API passed the technical review by the Drug Evaluation Center of the National Medical Products Administration, and was displayed on the CDE API, pharmaceutical excipients and pharmaceutical packaging materials registration information publicity platform The registration status indicator is changed to "A".
